Drugs / CD123-CD33 cCAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04156256 | Mar 2018 → Sep 2020 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD123-CD33 cCAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156256 ↗ |
| Known as | CD123-CD33 cCAR | “CD123-CD33 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressed on a T-cell, directed against the surface...” NCT04156256 ↗ |
| Action | Deplete | “Targeting both bulk disease and leukemic stem cells together allows for a more comprehensive ablation of the disease.” NCT04156256 ↗ |
| Modality | Cell therapy | “CD123-CD33 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressed on a T-cell” NCT04156256 ↗ |